LTR Pharma has officially debuted on the Australian Securities Exchange (ASX) under ticker code LTP.

Our foremost priority is to execute a bioequivalence trial of SPONTAN® to support expedited regulatory approvals, and to market and sell SPONTAN in the United States and Australia, first. 

We have a highly experienced team of pharmaceutical developers and commercialisation experts driving this program forward – and valued investors backing us too.

Investment Highlights

Successful clinical study

Successful phase I human proof of concept study now complete. SPONTAN® has shown to be six times faster than oral PDE5 inhibitors.

Blockbuster PDE5 inhibitor market

On track to register the first PDE5 inhibitor nasal spray, in a market estimated to reach US$6.0B in 2028.

Clear commercial pathway

Progressing to bioequivalence study, with expedited regulatory filings in the United States and Australia within 1-2 years.

LTP Share Price

ASX Announcements

Click here to learn more about SPONTAN®.

Latest news

Receive our latest news and investor updates

By entering your email address you are agreeing to our privacy policy.